DK1398037T3 - Farmaceutiske formuleringer, der omfatter et vanduoplöseligt kompleks til langvarig levering af lægemiddelstof - Google Patents

Farmaceutiske formuleringer, der omfatter et vanduoplöseligt kompleks til langvarig levering af lægemiddelstof

Info

Publication number
DK1398037T3
DK1398037T3 DK03017263T DK03017263T DK1398037T3 DK 1398037 T3 DK1398037 T3 DK 1398037T3 DK 03017263 T DK03017263 T DK 03017263T DK 03017263 T DK03017263 T DK 03017263T DK 1398037 T3 DK1398037 T3 DK 1398037T3
Authority
DK
Denmark
Prior art keywords
long
water
drug delivery
pharmaceutical formulations
insoluble complex
Prior art date
Application number
DK03017263T
Other languages
Danish (da)
English (en)
Inventor
Malcolm L Gefter
Gary Musso
Nicholas Barker
Christopher J Molineaux
Original Assignee
Praecis Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc
Application granted granted Critical
Publication of DK1398037T3 publication Critical patent/DK1398037T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Nanotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK03017263T 1996-12-11 1997-12-11 Farmaceutiske formuleringer, der omfatter et vanduoplöseligt kompleks til langvarig levering af lægemiddelstof DK1398037T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/762,747 US5968895A (en) 1996-12-11 1996-12-11 Pharmaceutical formulations for sustained drug delivery
PCT/US1997/022881 WO1998025642A2 (fr) 1996-12-11 1997-12-11 Formulations pharmaceutiques pour administration de medicaments a liberation prolongee

Publications (1)

Publication Number Publication Date
DK1398037T3 true DK1398037T3 (da) 2008-05-26

Family

ID=25065930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03017263T DK1398037T3 (da) 1996-12-11 1997-12-11 Farmaceutiske formuleringer, der omfatter et vanduoplöseligt kompleks til langvarig levering af lægemiddelstof

Country Status (34)

Country Link
US (4) US5968895A (fr)
EP (4) EP1878437B1 (fr)
JP (3) JP4033498B2 (fr)
KR (2) KR101114618B1 (fr)
CN (2) CN100522239C (fr)
AR (1) AR010351A1 (fr)
AT (3) ATE383165T1 (fr)
AU (1) AU735174B2 (fr)
BR (1) BR9714015A (fr)
CA (1) CA2274847A1 (fr)
CO (1) CO4910114A1 (fr)
CZ (1) CZ301119B6 (fr)
DE (2) DE69738460D1 (fr)
DK (1) DK1398037T3 (fr)
DZ (1) DZ2371A1 (fr)
ES (1) ES2299192T3 (fr)
HR (1) HRP970674A2 (fr)
HU (1) HUP0000299A3 (fr)
IL (3) IL130309A (fr)
JO (1) JO1998B1 (fr)
MA (1) MA26456A1 (fr)
NZ (4) NZ537042A (fr)
PE (1) PE20000008A1 (fr)
PL (2) PL200675B1 (fr)
PT (1) PT952843E (fr)
RU (1) RU2202371C2 (fr)
SI (1) SI0952843T1 (fr)
SK (1) SK287305B6 (fr)
TN (1) TNSN97205A1 (fr)
TR (1) TR199901382T2 (fr)
UA (1) UA68343C2 (fr)
UY (2) UY24806A1 (fr)
WO (1) WO1998025642A2 (fr)
ZA (1) ZA9710994B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6197337B1 (en) * 1999-05-10 2001-03-06 Kenneth Weisman Therapeutic uses of abarelix
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
KR100452752B1 (ko) * 2000-04-18 2004-10-12 주식회사 펩트론 단백질 함유 서방성 제제를 제조하는 방법 및 그 제제
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001289079A1 (en) * 2000-09-13 2002-03-26 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
AU2002235348A1 (en) * 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
EP1383376A4 (fr) * 2001-03-19 2006-03-08 Praecis Pharm Inc Formulations pharmaceutiques a liberation prolongee
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
CA2451187C (fr) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
SE0104463D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
RS52966B (sr) * 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
SI1551876T1 (sl) 2002-10-16 2011-07-29 Purdue Pharma Lp Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
JP2006523609A (ja) * 2002-12-31 2006-10-19 アルタス ファーマシューティカルズ インコーポレイテッド タンパク質結晶およびイオン性ポリマーの複合体
CA2512052C (fr) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Cristaux d'hormone de croissance humaine et procedes de preparation correspondants
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7833545B2 (en) * 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
CA2866501A1 (fr) 2003-11-10 2005-05-26 Allergan, Inc. Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US20060067971A1 (en) * 2004-09-27 2006-03-30 Story Brooks J Bone void filler
EP1674082A1 (fr) * 2004-12-22 2006-06-28 Zentaris GmbH Procédé pour la manufacture des suspensions ou lyophilisates steriles des complexes mal-soluble de peptides basic, des formulations pharmaceutiques avec ces complexes et leur utilisation comme medicament
JP2008539260A (ja) * 2005-04-25 2008-11-13 アムジエン・インコーポレーテツド ポロゲンを含む生分解性プチド徐放性組成物
CA2606386C (fr) * 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Compositions therapeutiques
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
WO2007021970A2 (fr) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Formes pharmaceutiques stables et methodes d'utilisation de celles-ci
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
WO2007076131A2 (fr) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprenant des cristaux de proteines complexes par des polycations et procede de traitement associe
KR101353706B1 (ko) * 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
WO2007149508A2 (fr) 2006-06-19 2007-12-27 The University Of The Sciences In Philadelphia Antagonistes non compétitifs du récepteur nmda
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
MX2009002985A (es) * 2006-09-19 2009-04-01 Genzyme Corp Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (tsh).
MX2009011785A (es) * 2007-05-02 2010-03-04 Tyrx Pharma Inc Polimeros de dihidroxibenzoato y usos de los mismos.
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2730603C (fr) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
ES2319158B1 (es) * 2008-12-23 2010-01-26 Grifols, S.A Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP2012528718A (ja) 2009-06-02 2012-11-15 マサチューセッツ インスティテュート オブ テクノロジー コーティング
US20120058355A1 (en) 2009-06-02 2012-03-08 Hyomin Lee Coatings
PT2442821T (pt) 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
EP3366301A1 (fr) * 2012-05-14 2018-08-29 Teijin Limited Composition de protéines résistant à une stérilisation par rayonnement
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
KR101586791B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP3718557A3 (fr) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Agoniste du récepteur de la guanylate cyclase sp-333 à utiliser lors du nettoyage du côlon
PT2970389T (pt) * 2013-03-15 2020-10-21 Rhythm Pharmaceuticals Inc Composições farmacêuticas
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
CA2851912C (fr) 2013-05-14 2022-08-30 Scimar Ltd. Substance sensibilisant a l'insuline hepatique et repas d'epreuve pour sensibilisation a l'insuline
CN104418936B (zh) * 2013-08-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 Lhrh拮抗剂衍生物及其药物用途
WO2015054649A2 (fr) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles induits par les opioïdes
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
EP3920899A2 (fr) 2019-02-08 2021-12-15 The UAB Research Foundation Composition pour le traitement et la prévention de la maladie inflammatoire chronique de l'intestin
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
FR2455459A1 (fr) * 1979-05-02 1980-11-28 Sertog Procede d'obtention d'une matrice contenant un principe actif et le liberant progressivement
US4431635A (en) 1979-06-13 1984-02-14 Coy David Howard LH-RH Antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4547370A (en) 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
CA1256638A (fr) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymere, et sa production
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
WO1988005661A1 (fr) * 1987-01-30 1988-08-11 Biomed Research Consultants, Limited Compositions pharmaceutiques a base de vasopressine
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
US4851385A (en) 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3886880T2 (de) * 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
DD269785A1 (de) * 1988-02-08 1989-07-12 Univ Dresden Tech Verfahren zur herstellung von aktivitaetsstabilisierten und in ihren pharmakologischen eigenschaften modifizierten peptidderivaten
US5300492A (en) 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
DE68928278T2 (de) * 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US4992421A (en) 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5171835A (en) 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
US5356630A (en) * 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
US5049395A (en) * 1989-03-09 1991-09-17 Micro Vesicular Systems, Inc. Controlled release vehicle
US4980150A (en) * 1989-04-27 1990-12-25 Zetachron, Inc. Chlorhexidine complex
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
AU653325B2 (en) * 1990-02-12 1994-09-29 Lucky Limited A composition durably releasing bioactive polypeptides
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2046830C (fr) * 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
WO1994008566A1 (fr) * 1992-10-21 1994-04-28 Micro Vesicular Systems, Inc. Vehicule et procede d'emprisonnement de matieres actives
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
ATE183641T1 (de) * 1992-12-23 1999-09-15 Saitec Srl Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
JPH08505395A (ja) * 1993-01-06 1996-06-11 キナートン リミティド 生物分解性ポリエステルと生物活性ポリペプチドのイオン分子結合体
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
NZ260933A (en) * 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
US5413990A (en) 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
JP3862304B2 (ja) * 1994-09-09 2006-12-27 武田薬品工業株式会社 徐放性製剤
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE19712718C2 (de) 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US9609852B2 (en) 2014-06-20 2017-04-04 Brome Bird Care Inc. Lantern shaped bird feeder

Also Published As

Publication number Publication date
PL200675B1 (pl) 2009-01-30
HUP0000299A3 (en) 2000-09-28
NZ537042A (en) 2006-12-22
HK1064918A1 (en) 2005-02-08
US6180608B1 (en) 2001-01-30
CN1245436A (zh) 2000-02-23
HRP970674A2 (en) 1998-08-31
CO4910114A1 (es) 2000-04-24
TNSN97205A1 (fr) 2005-03-15
ES2299192T3 (es) 2008-05-16
AU735174B2 (en) 2001-07-05
NZ336269A (en) 2002-02-01
US20030171296A1 (en) 2003-09-11
IL130309A (en) 2007-06-17
MA26456A1 (fr) 2004-12-20
KR20110122773A (ko) 2011-11-10
IL130309A0 (en) 2000-06-01
CZ206699A3 (cs) 1999-11-17
AU5699198A (en) 1998-07-03
US5968895A (en) 1999-10-19
PT952843E (pt) 2008-04-15
HK1023282A1 (en) 2000-09-08
TR199901382T2 (xx) 1999-08-23
CN101596306A (zh) 2009-12-09
ZA9710994B (en) 1998-07-10
EP1398037A2 (fr) 2004-03-17
HUP0000299A1 (hu) 2000-06-28
UA68343C2 (en) 2004-08-16
ATE383165T1 (de) 2008-01-15
PL199121B1 (pl) 2008-08-29
JP2007016049A (ja) 2007-01-25
DE69738300T2 (de) 2008-09-04
WO1998025642A3 (fr) 1998-07-23
EP0952843A2 (fr) 1999-11-03
JO1998B1 (en) 1999-05-15
CN100522239C (zh) 2009-08-05
EP0952843B1 (fr) 2007-11-14
CZ301119B6 (cs) 2009-11-11
SK79399A3 (en) 2000-01-18
SI0952843T1 (sl) 2008-10-31
DZ2371A1 (fr) 2002-12-28
ATE516812T1 (de) 2011-08-15
JP2011105760A (ja) 2011-06-02
ATE378059T1 (de) 2007-11-15
CA2274847A1 (fr) 1998-06-18
EP1878437A2 (fr) 2008-01-16
EP1398037A3 (fr) 2004-04-14
EP1398037B1 (fr) 2008-01-09
IL180450A0 (en) 2007-06-03
IL180449A0 (en) 2007-06-03
JP2000508345A (ja) 2000-07-04
RU2202371C2 (ru) 2003-04-20
DE69738460D1 (de) 2008-02-21
US6699833B1 (en) 2004-03-02
NZ579443A (en) 2011-07-29
UY24806A1 (es) 1998-06-09
KR20000069432A (ko) 2000-11-25
PE20000008A1 (es) 2000-01-19
UY25030A1 (es) 2001-08-27
AR010351A1 (es) 2000-06-07
KR101114618B1 (ko) 2012-03-05
WO1998025642A2 (fr) 1998-06-18
BR9714015A (pt) 2000-05-09
PL334076A1 (en) 2000-01-31
SK287305B6 (sk) 2010-06-07
JP4033498B2 (ja) 2008-01-16
DE69738300D1 (de) 2007-12-27
EP1878437A3 (fr) 2008-11-12
EP2316471A1 (fr) 2011-05-04
EP1878437B1 (fr) 2011-07-20
NZ568189A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
DK0998304T3 (da) Farmaceutisk præparat. der omfatter et basisk lægemiddel, en cyclodextrin, en polymer og en syre
EE200100714A (et) Farmatseutiliste ravimvormide pihustamissüsteemidja -meetodid
DK0633796T3 (da) Ballonkateter til afgivelse af lægemiddel
NO994837D0 (no) Intravesikal medikamentavleveringssystem
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
NO974618D0 (no) Farmasöytiske preparater for intranasal administrasjon
DK1037667T3 (da) Farmaceutiske hydrogelformuleringer, lægemiddelindgivelsesanordninger samt fremgangsmåder
TR199901077A3 (tr) Ispençiyari formülasyonlar.
DK1041975T3 (da) Hastighedskontrollerende membraner til anordninger til kontrolleret indførsel af medikament
HUP0000299A3 (en) Pharmaceutical formulations for sustained drug delivery
DE69530325D1 (de) Aerosol-arzneiformulierungen
DK1035833T3 (da) Sammensætning til nasal indgivelse
BR9801027B1 (pt) sistema de distribuiÇço de medicamentos.
DE60016271D1 (de) Medikamentenzuführvorrichtung
DK1100474T5 (da) Todelt kapsel til optag af farmaceutiske tilberedninger til inhalatorer
NO20004196D0 (no) Innretninger for legemiddelavlevering
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
EE05375B1 (et) LevosimendaniÁfarmatseutilineÁlahus
ATE311173T1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
DK0868911T3 (da) Rapamycinpræparater til oral indgivelse
FI970331A0 (fi) Lääkkeen antokoostumus virustenvastaisten aineiden nenään toteutettavaa antoa varten
ID16781A (id) Formulasi-formulasi farmasi
TR199501082A2 (tr) Farmasötik formülasyonlar.
DK0994697T3 (da) Rapamycinformuleringer til oral indgivelse
BR9707827A (pt) Formulações farmacêuticas de liberação prolongada contendo a mizolastina